Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ebix Inc (NEBIX) News: Goldman Sachs Group, Inc. (GS) Deal Cancelled, Shares Drop, Constant Contact Inc (CTCT) & More

Editor’s Note: Related Tickers: Ebix Inc (NASDAQ:EBIX), Goldman Sachs Group, Inc. (NYSE:GS), Constant Contact Inc (NASDAQ:CTCT), Microsoft Corporation (NASDAQ:MSFT)

Goldman Sachs Drops Ebix Deal as Prosecutors Open Probe (Bloomberg)
Goldman Sachs Group, Inc. (NYSE:GS) terminated an agreement to acquire Ebix Inc (NASDAQ:EBIX) after the insurance software maker said it was told that federal prosecutors had opened an investigation. Ebix shares plunged the most in three years. The U.S. Attorney in Atlanta wrote in a letter that it was probing allegations of intentional misconduct, Ebix said yesterday in a statement. The company previously disclosed that it faced shareholder class-action lawsuits and a U.S. Securities and Exchange Commission probe over the accuracy of its public statements to investors.

Ebix Inc (NASDAQ:EBIX)Ebix Shares Hit 3-Year Low After Federal Probe Scuttles Buyout (4-traders)
Shares of insurance software provider Ebix Inc (NASDAQ:EBIX) sank to their lowest level in more than three years after a federal investigation prompted Goldman Sachs Group, Inc. (NYSE:GS) to withdraw its $780 million offer to buy the company. The deal’s demise, triggered by news the U.S. attorney for northern Georgia launched a formal probe into the company’s accounting and reporting practices, sent Ebix Inc (NASDAQ:EBIX)’s stock as low as $9.85 Thursday, its worst point since May 2010. Shares recently traded 41% lower at $11.56, erasing nearly $300 million of the company’s market value.

Ebix Joins Constant Contact’s AppConnect Partner Program (Destination CRM)
Constant Contact Inc (NASDAQ:CTCT) today announced that Ebix Inc (NASDAQ:EBIX) has joined its AppConnect Partner Program to integrate the Ebix SmartOffice Customer Relationship Management (CRM) solution with Constant Contact’s Email Marketing tool to help Ebix’s customers harness critical data to drive successful email marketing campaigns. The integration now enables the more than 100,000 SmartOffice CRM users to sync their existing contacts and filtered lists with Constant Contact’s Email Marketing tool. SmartOffice CRM users who don’t have a Constant Contact Inc (NASDAQ:CTCT) account can also create one directly through SmartOffice CRM.

The Actual Story Behind These Stocks : RHT, SCS, EBIX, FCEL, PGNX (SBWire)
Ebix Inc (NASDAQ:EBIX) reported EPS in 1.851. For the Current Fiscal year, the company is expected to report EPS of 1.81. For the Next Quarter and Next Year, the company is expected to report EPS of 0.45 and 1.97 respectively. At Current Market Price, EBIX is in distance of -41.81% from its 50-day Moving Average price of $19.644 and -33.64% from its 200-day Moving Average price of $17.223.

Ebix To Deliver Multimedia Health Content on Bing (IT News Online)
Ebix Inc (NASDAQ:EBIX), announced that the company’s A.D.A.M. multimedia health content will be included on Bing, Microsoft Corporation (NASDAQ:MSFT)’s search engine. More than 59 percent of all U.S. adults go online to search for health information.* Now, when people search on Bing, they will find information from the US National Library of Medicine which licenses its data from Ebix. A.D.A.M. multimedia health content provides access to the authoritative Health Answer from the National Institute of Health and other public and private health-related organizations. A.D.A.M.’s content provides health consumers with a comprehensive online health information database complete with thousands of physician-written and reviewed articles covering conditions, procedures, treatments, surgeries, and tests in an easy-to-navigate format.

Loading Comments...